These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27264843)

  • 1. Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
    Okada K; Nakano Y; Yamasaki K; Nitani C; Fujisaki H; Hara J
    Cancer Med; 2016 Aug; 5(8):1947-9. PubMed ID: 27264843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
    Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining sorafenib therapy: lessons from clinical practice.
    Bolondi L; Craxi A; Trevisani F; Daniele B; Di Costanzo GG; Fagiuoli S; Cammà C; Bruzzi P; Danesi R; Spandonaro F; Boni C; Santoro A; Colombo M
    Future Oncol; 2015; 11(3):449-65. PubMed ID: 25360997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
    Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib for the treatment of multiple myeloma.
    Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
    Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
    BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
    Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
    Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.